{"public_id":"co_4a4740f0a3f1a2377013c2ce91c3f5c5","status":"active","merged_into_public_id":null,"resolved_public_id":"co_4a4740f0a3f1a2377013c2ce91c3f5c5","name":"extramedullary disease","description":"An uncommon manifestation in multiple myeloma where plasma cells form tumors outside the bone marrow.","aliases":[],"types":["condition"],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":1,"verifier_classes":["system"],"verifier_class_counts":{"system":1,"user_agent":0},"verdict_counts":{"approve":1,"reject":0},"verifier_state":"system_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":1764643,"title":"Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents","citation_count":359,"url":"https://sah.borca.ai/papers/1764643"}],"claims":[{"public_id":"cl_4f4eaffa73c5a8aa7486eade5fef239e","text":"The most common sites for extramedullary disease at diagnosis were skin and soft tissue, whereas liver involvement was the striking feature at disease relapse or progression.","corpus_id":1764643,"url":"https://sah.borca.ai/claims/cl_4f4eaffa73c5a8aa7486eade5fef239e"},{"public_id":"cl_6fcdaa29daa197e3f0a6d44d9b0f27bd","text":"Extramedullary disease is more prevalent in genomically defined high-risk multiple myeloma, including the MF subtype (MAF subtype) and the PR subtype (Proliferation subtype).","corpus_id":1764643,"url":"https://sah.borca.ai/claims/cl_6fcdaa29daa197e3f0a6d44d9b0f27bd"},{"public_id":"cl_dc3a0869289cb30f201cff4d26d4a204","text":"Extramedullary disease is associated with shorter progression-free survival and overall survival in multiple myeloma patients, even in the era of novel agents.","corpus_id":1764643,"url":"https://sah.borca.ai/claims/cl_dc3a0869289cb30f201cff4d26d4a204"},{"public_id":"cl_f266c09a3a096d431b9848eb56fd2dc6","text":"Multivariate analysis with logistic regression revealed that extramedullary disease is more prevalent in patients with an elevated centrosome index, as determined by gene expression profiling.","corpus_id":1764643,"url":"https://sah.borca.ai/claims/cl_f266c09a3a096d431b9848eb56fd2dc6"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_4a4740f0a3f1a2377013c2ce91c3f5c5","url":"https://sah.borca.ai/concepts/co_4a4740f0a3f1a2377013c2ce91c3f5c5"}